Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOL-303259-X dose-finding study versus latanoprost in open-angle glaucoma or ocular hypertension
2010-022178-14Phase 2Completed
- Sponsor
- Dr Gerhard Mann
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of latanoprostene bunod in open-angle glaucoma (OAG) and ocular hypertension (5 arms), sponsored by Dr Gerhard Mann. Primary endpoint: Reduction in mean diurnal intraocular pressure on Day 28. Started Nov 2010; status: completed.
02
Drugs
latanoprostene bunod
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2010-022178-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022178-14.